It combines the elements of the original ISS of MM (serum beta-2 microglobulin (B2M) and albumin), chromosomal abnormalities detected by FISH, and serum LDH levels in order to create a tool that can effectively determine the relative risk of survival of newly diagnosed MM patients [63]. Here, B2M is linked to Miyoshi myopathy.